AI assistant
RENALYTIX PLC Director's Dealing 2021
7877_dirs_2021-09-06_3fe77d3a-2a7e-4aa7-b9c7-f51dcf89411d.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 8886K
Renalytix PLC
06 September 2021
Renalytix plc
("Renalytix" or the "Company")
Director/PDMR Dealing
New York, 6 September 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by O. James Sterling, the Company's Chief Financial Officer, of 3,000 American Depositary Shares ("ADS"), each representing two ordinary shares of £0.0025 each in the capital of the Company ("Ordinary Shares"), under a Rule 10b5-1 trading plan established in accordance with Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").
Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, or inside information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future.
Following completion of the sale, O. James Sterling is interested in 1,805,236 Ordinary Shares representing 2.50% of the current issued share capital of the Company.
For further information, please contact:
| Renalytix plc | www.renalytix.com | |
| James McCullough, CEO | Via Walbrook PR | |
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
| Alex Price / Nicholas Moore | ||
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
| Gary Clarence / Daniel Adams | ||
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | |
| Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | |
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.
* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com
The information contained in this notification is disclosed in accordance with the requirements of MAR.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | O. James Sterling | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Renalytix plc | |
| b) | Legal Entity Identifier | 213800NTOH3FK3WER551 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
ADS', each ADS representing two Ordinary Shares of £0.0025 each. US75973T1016 |
|
| b) | Nature of the transaction | Sale of ADS' under a 10b5-1 trading plan | |
| c) | Currency | US Dollar | |
| d) | Price(s) and volume(s) | Price(s) | Volume(s) |
| $28.888170001 | 3,000 ADS (representing 6,000 Ordinary Shares) | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
3,000 ADS (representing 6,000 Ordinary Shares) $28.888170001 $86,664.51 |
|
| f) | Date of the transaction | 31 August 2021 | |
| g) | Place of the transaction | Nasdaq Stock Exchange |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEASNKEDAFEFA